Identification of potential HIV-1 targets of minocycline

Bioinformatics

Volumn 23, Issue 20, 2007, Pages 2797-2799

  Jenwitheesuk, Ekachai ^a,b   Samudrala, Ram ^b  

^a NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; MINOCYCLINE; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; DRUG PROTEIN BINDING; DRUG TARGETING; DYNAMICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VITRO STUDY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 35748954342     PISSN: 13674803     EISSN: 13674811     Source Type: Journal    
DOI: 10.1093/bioinformatics/btm424     Document Type: Article

References (12)

1. Artico,M. et al. (1998) Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. J. Med. Chem., 41, 3948-3960.
2. Darcissac,E.C. et al. (2000) The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells. J. Virol., 74, 7794-7802.
3. Goldgur,Y. et al. (1999) Structure of the HIV-1 integrase catalytic domain domplexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. USA., 96, 13040-13043.
4. Goodsell,D.S. et al. (1996) Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit., 9, 1-5.
5. Jenwitheesuk,E. and Samudrala,R. (2003) Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC. Struct. Biol., 3, 2.
6. Jenwitheesuk,E. and Samudrala,R. (2005) Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Antivir. Ther., 10, 157-166.
7. Schuttelkopf,A.W. and van Aalten,D.M. (2004) PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta. Crystallogr. D Biol. Crystallogr., 60, 1355-1363.
8. Si,Q. et al. (2004) A novel action of minocycline: Inhibition of human immunodeficiency virus type 1 infection in microglia. J. Neurovirol., 10, 284-292.
9. Sui,Z. et al. (1993) Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg. Med. Chem., 1 415-422.
10. Vajragupta,O. et al. (2005) Active site binding modes of curcumin in HIV-1 protease and integrase. Bioorg. Med. Chem. Lett., 15 3364-3368.
11. Wondrak,E.M. et al. (1988) Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerase alpha, beta and gamma by phosphonoformic acid and other drugs. J. Antimicrob. Chemother, 21, 151-161.
12. Zink,M.C. et al. (2005) Neuroprotective and anti-human immunodeficiency virus activity of minocycline. J. Am. Med. Assoc. 293, 2003-2011.